Michelle A. Fravel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michelle A. Fravel has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- Michael E. Ernst
Department of Pharmacy Practice and Science, College of Pharmacy, The University of Iowa , Iowa City, IA
8 shared publications - Joanne Ryan
School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia
5 shared publications Kevan R. Polkinghorne
Department of Nephrology, Monash Medical Centre, Monash Health, Melbourne, Victoria, Australia
5 shared publications- Suzanne Gaye Orchard
School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
5 shared publications Robyn L. Woods
School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
4 shared publications- Robyn Lorraine Woods
School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia
4 shared publications
Latest Publications
- Open Access
- 16 June 2026
- Published by Wolters Kluwer Health in Kidney360
Association between eGFR and Disability-Free Survival in Older Adults Varies by Physical Function
Background: Ascertaining the clinical relevance of reduced eGFR in older adults is challenging, particularly in those who may have decreased creatinine due to low muscle mass. This study investigated the potential of gait speed and grip strength (markers of muscle mass) to support the clinical interpretation of eGFR and its association with disability-free survival in older adults. Methods: This was a cohort study of the ASPirin in Reducing Events in the Elderly (ASPREE) randomized trial and the ASPREE-eXtension observational follow-up study. Participants were recruited from community-based clinics. ASPREE enrolled adults aged ≥70 years, with African American and Hispanic adults eligible from age ≥65 years, all of whom were free of significant co-morbidity at baseline. Baseline eGFR categories (2 ) combined with gait speed (2 and slow gait’ or ‘eGFR 60-79mL/min/1.73m 2 and not weak’. Results: There were 16,925 participants, median follow-up was 8.4 years (interquartile range [IQR]:2.7,9.6), mean age was 75.0±4.5 years, and median eGFR was 79mL/min (IQR:68,89). In the presence of normal gait speed or grip strength, eGFR 2 did not increase the risk for disability-free survival or its components. Slow gait or weak grip accompanying any eGFR was associated with reduced disability-free survival, increased mortality, or increased disability. E.g: participants with eGFR ≥80mL/min/1.73m 2 and slow gait were at risk for dementia (HR:1.48, 95%CI:1.23-1.79). Conclusions: In older, initially healthy adults, assessment of gait speed and grip strength may provide additional context when examining associations between eGFR and disability-free survival and its individual components.
- 16 June 2026
- Published by Wolters Kluwer Health in Kidney360
Open AccessAssociation between eGFR and Disability-Free Survival in Older Adults Varies by Physical Function
Background: Ascertaining the clinical relevance of reduced eGFR in older adults is challenging, particularly in those who may have decreased creatinine due to low muscle mass. This study investigated the potential of gait speed and grip strength (markers of muscle mass) to support the clinical interpretation of eGFR and its association with disability-free survival in older adults. Methods: This was a cohort study of the ASPirin in Reducing Events in the Elderly (ASPREE) randomized trial and the ASPREE-eXtension observational follow-up study. Participants were recruited from community-based clinics. ASPREE enrolled adults aged ≥70 years, with African American and Hispanic adults eligible from age ≥65 years, all of whom were free of significant co-morbidity at baseline. Baseline eGFR categories (2 ) combined with gait speed (2 and slow gait’ or ‘eGFR 60-79mL/min/1.73m 2 and not weak’. Results: There were 16,925 participants, median follow-up was 8.4 years (interquartile range [IQR]:2.7,9.6), mean age was 75.0±4.5 years, and median eGFR was 79mL/min (IQR:68,89). In the presence of normal gait speed or grip strength, eGFR 2 did not increase the risk for disability-free survival or its components. Slow gait or weak grip accompanying any eGFR was associated with reduced disability-free survival, increased mortality, or increased disability. E.g: participants with eGFR ≥80mL/min/1.73m 2 and slow gait were at risk for dementia (HR:1.48, 95%CI:1.23-1.79). Conclusions: In older, initially healthy adults, assessment of gait speed and grip strength may provide additional context when examining associations between eGFR and disability-free survival and its individual components.
- 12 August 2025
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 8 (9) , 951-961
Education and Training of Today's Clinical Pharmacist
Today's clinical pharmacists have graduated from a doctor of pharmacy professional degree program, completed residency training, and obtained board certification. Their foundational education consists of an extensive didactic and experiential curriculum with a strong focus on pharmacology and pharmacotherapeutics. The credit hours devoted to pharmacology and pharmacotherapeutics are substantially greater than those of other health care professional degree programs. When combined with the clinical learning acquired through formal, postgraduate residency training, clinical pharmacists are well prepared to address medication therapy problems and serve as essential members of interprofessional health care teams. This commentary details the education and training of clinical pharmacists and how these compare with other members of the health care team and concludes that clinical pharmacists are uniquely positioned to optimize medication outcomes.
- 12 August 2025
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 8 (9) , 951-961
Education and Training of Today's Clinical Pharmacist
Today's clinical pharmacists have graduated from a doctor of pharmacy professional degree program, completed residency training, and obtained board certification. Their foundational education consists of an extensive didactic and experiential curriculum with a strong focus on pharmacology and pharmacotherapeutics. The credit hours devoted to pharmacology and pharmacotherapeutics are substantially greater than those of other health care professional degree programs. When combined with the clinical learning acquired through formal, postgraduate residency training, clinical pharmacists are well prepared to address medication therapy problems and serve as essential members of interprofessional health care teams. This commentary details the education and training of clinical pharmacists and how these compare with other members of the health care team and concludes that clinical pharmacists are uniquely positioned to optimize medication outcomes.
- 1 June 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 18 (6) , e011719
Performance of the American Heart Association PREVENT Cardiovascular Risk Equations in Older Adults
BACKGROUND: The ability of the American Heart Association Predicting Risk of Cardiovascular Disease Events (PREVENT) calculator to accurately assign 10-year atherosclerotic cardiovascular disease (ASCVD) risk in older individuals, including those aged ≥80 years, is unknown. This study compares PREVENT with the 2013 Pooled Cohort Equation (PCE) calculator for predicting 10-year ASCVD risk in a large cohort of older adults. METHODS: This was a prospective cohort study of adults without CVD from Australia and the United States aged ≥70 years (≥65 years, if US minorities). They were enrolled from 2010 to 2014 in the ASPREE trial (Aspirin in Reducing Events in the Elderly), a 5-year randomized trial of low-dose aspirin in community-dwelling older adults with posttrial observational follow-up extending to 2022. ASCVD events were adjudicated by expert panels. The discriminative ability of the 2 risk calculators was assessed by Harell C statistic following Cox regression in the 65- to 79-year age group and >80-year age group, separately. For calibration, predicted event numbers were calculated using PREVENT and PCE, scaled for the actual length of follow-up, and compared with the number of observed events in-trial and during extended follow-up. RESULTS: Among the 15 510 participants aged 65 to 79 years (median age, 73.2 years; 56.1% women), 1084 ASCVD events occurred (median follow-up, 8.3 years); PCE predicted 3102 events while PREVENT predicted 1290 events. For the 2787 participants ≥80 years (median age, 82.6 years; 59.2% women), 355 ASCVD events occurred (median follow-up, 7.4 years); PCE predicted 1067 events while PREVENT predicted 350 events. PREVENT showed superior discriminative performance compared with PCE (PREVENT versus PCE, C statistic, 0.793 versus 0.740; P P <0.001 in those aged ≥80 years). CONCLUSIONS: The PREVENT risk calculator is superior to the PCE calculator in predicting ASCVD events in older adults from the United States and Australia, including those aged ≥80 years. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01038583. URL: https://www.isrctn.com ; Unique identifier: ISRCTN83772183.
- 1 June 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 18 (6) , e011719
Performance of the American Heart Association PREVENT Cardiovascular Risk Equations in Older Adults
BACKGROUND: The ability of the American Heart Association Predicting Risk of Cardiovascular Disease Events (PREVENT) calculator to accurately assign 10-year atherosclerotic cardiovascular disease (ASCVD) risk in older individuals, including those aged ≥80 years, is unknown. This study compares PREVENT with the 2013 Pooled Cohort Equation (PCE) calculator for predicting 10-year ASCVD risk in a large cohort of older adults. METHODS: This was a prospective cohort study of adults without CVD from Australia and the United States aged ≥70 years (≥65 years, if US minorities). They were enrolled from 2010 to 2014 in the ASPREE trial (Aspirin in Reducing Events in the Elderly), a 5-year randomized trial of low-dose aspirin in community-dwelling older adults with posttrial observational follow-up extending to 2022. ASCVD events were adjudicated by expert panels. The discriminative ability of the 2 risk calculators was assessed by Harell C statistic following Cox regression in the 65- to 79-year age group and >80-year age group, separately. For calibration, predicted event numbers were calculated using PREVENT and PCE, scaled for the actual length of follow-up, and compared with the number of observed events in-trial and during extended follow-up. RESULTS: Among the 15 510 participants aged 65 to 79 years (median age, 73.2 years; 56.1% women), 1084 ASCVD events occurred (median follow-up, 8.3 years); PCE predicted 3102 events while PREVENT predicted 1290 events. For the 2787 participants ≥80 years (median age, 82.6 years; 59.2% women), 355 ASCVD events occurred (median follow-up, 7.4 years); PCE predicted 1067 events while PREVENT predicted 350 events. PREVENT showed superior discriminative performance compared with PCE (PREVENT versus PCE, C statistic, 0.793 versus 0.740; P P <0.001 in those aged ≥80 years). CONCLUSIONS: The PREVENT risk calculator is superior to the PCE calculator in predicting ASCVD events in older adults from the United States and Australia, including those aged ≥80 years. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01038583. URL: https://www.isrctn.com ; Unique identifier: ISRCTN83772183.
- Open Access
- 30 April 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 118 (2) , 337-342
Prevalence of Actionable Pharmacogenetic Genotype Frequencies, Cautionary Medication Use, and Polypharmacy in Community‐Dwelling Older Adults
Older adults (65 years and over) frequently manage complex medication regimens and are vulnerable to adverse drug reactions and treatment inefficacies, some of which could be preventable with pharmacogenetics (PGx)‐guided prescribing. This study examined the prevalence of actionable PGx genotypes (i.e., those linked to a guideline that recommends a change to standard prescribing), the use of cautionary medications (i.e., those associated with an actionable PGx genotype), polypharmacy (i.e., ≥ 5 medications simultaneously), and cytochrome P450 enzyme inhibitor and inducer use among 13,670 older adults enrolled in the ASPirin in Reducing Events in the Elderly (ASPREE) trial. Genotyping was conducted for 10 pharmacogenes with actionable PGx‐based prescribing guidelines. Medication data were collected annually and assessed to identify cautionary medication use in the cohort. Most participants (98.8%) carried at least one actionable PGx genotype, with an average of three actionable genotypes per participant. VKORC1 (61.1%) and CYP2C19 (59.6%) were the most frequently observed genes with actionable genotypes. Statins (29.3%), nonsteroidal anti‐inflammatory drugs (14.2%), and proton‐pump inhibitors (7.9%) were the most used cautionary medications, with 27.5% of participants taking at least one medication for which PGx guidelines recommended a deviation from standard prescribing. Most (83.9%) participants reported taking a polypharmacy regimen, and 68.2% reported use of at least one cytochrome P450 enzyme inhibitor or inducer during the trial. Our findings underscore the high prevalence of actionable PGx genotypes, polypharmacy, and use of inhibitors and inducers in older adults, which collectively have the potential to inform safer and more effective prescribing practices.
- 30 April 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 118 (2) , 337-342
Open AccessPrevalence of Actionable Pharmacogenetic Genotype Frequencies, Cautionary Medication Use, and Polypharmacy in Community‐Dwelling Older Adults
Older adults (65 years and over) frequently manage complex medication regimens and are vulnerable to adverse drug reactions and treatment inefficacies, some of which could be preventable with pharmacogenetics (PGx)‐guided prescribing. This study examined the prevalence of actionable PGx genotypes (i.e., those linked to a guideline that recommends a change to standard prescribing), the use of cautionary medications (i.e., those associated with an actionable PGx genotype), polypharmacy (i.e., ≥ 5 medications simultaneously), and cytochrome P450 enzyme inhibitor and inducer use among 13,670 older adults enrolled in the ASPirin in Reducing Events in the Elderly (ASPREE) trial. Genotyping was conducted for 10 pharmacogenes with actionable PGx‐based prescribing guidelines. Medication data were collected annually and assessed to identify cautionary medication use in the cohort. Most participants (98.8%) carried at least one actionable PGx genotype, with an average of three actionable genotypes per participant. VKORC1 (61.1%) and CYP2C19 (59.6%) were the most frequently observed genes with actionable genotypes. Statins (29.3%), nonsteroidal anti‐inflammatory drugs (14.2%), and proton‐pump inhibitors (7.9%) were the most used cautionary medications, with 27.5% of participants taking at least one medication for which PGx guidelines recommended a deviation from standard prescribing. Most (83.9%) participants reported taking a polypharmacy regimen, and 68.2% reported use of at least one cytochrome P450 enzyme inhibitor or inducer during the trial. Our findings underscore the high prevalence of actionable PGx genotypes, polypharmacy, and use of inhibitors and inducers in older adults, which collectively have the potential to inform safer and more effective prescribing practices.
- Open Access
- 22 April 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (9) , 1522-1531
Real-World Tolvaptan Use in Autosomal Dominant Polycystic Kidney Disease
Key Points: Twenty-seven percent of patients with autosomal dominant polycystic kidney disease discontinued tolvaptan in a real-world cohort in the midwestern United States. Most patients maintained tolvaptan on lower doses than trials, and a minority tolerated above the 45 mg (am)/15 mg (pm) starting dosage. Adverse effects, specifically aquaretic side effects, strongly influenced tolvaptan tolerability, dosage titration, and discontinuation. Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most prevalent genetic kidney disease leading to kidney failure. Tolvaptan, a vasopressin V2 receptor antagonist, is the only medication approved by the US Food and Drug Administration for slowing kidney growth in individuals with rapidly progressive ADPKD, but its long-term tolerability and effective implementation has yet to be studied, particularly in real-world clinical settings within the United States. Methods: This retrospective cohort study examined adults with ADPKD treated with tolvaptan at the University of Kansas Medical Center and the University of Iowa Hospitals & Clinics from May 2018 to April 2023. Data on demographics, clinical characteristics, tolvaptan dosage, and treatment duration were collected from electronic health records for an average follow-up duration of 28.2 months (interquartile range: 8.5–47.1 months). The study focused on examining tolvaptan dosage trends, treatment discontinuation reasons, and the impact of aquaretic side effects on dosage and adherence. Results: Of 134 patients, 27% stopped tolvaptan during the observational period, with 10.4% of the cohort withdrawing from treatment due to intolerance of aquaretic side effects. Most patients maintained a lower tolvaptan dosage (≤45/15 mg) than in clinical trials, with two thirds of individuals who underwent dosage adjustment undergoing net decrease in dosage. Adverse effects significantly influenced and dosage decisions, presenting a potential early barrier for adherence, particularly in female patients. Conclusions: The study highlights real-world challenges in the use of tolvaptan for ADPKD, particularly for side effects leading to high discontinuation rates and dosage adjustments. These findings underscore the need for standardized and improved management strategies to enhance tolerability and adherence, offering insights for future research and practice in the treatment of ADPKD with tolvaptan.
- 22 April 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (9) , 1522-1531
Open AccessReal-World Tolvaptan Use in Autosomal Dominant Polycystic Kidney Disease
Key Points: Twenty-seven percent of patients with autosomal dominant polycystic kidney disease discontinued tolvaptan in a real-world cohort in the midwestern United States. Most patients maintained tolvaptan on lower doses than trials, and a minority tolerated above the 45 mg (am)/15 mg (pm) starting dosage. Adverse effects, specifically aquaretic side effects, strongly influenced tolvaptan tolerability, dosage titration, and discontinuation. Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most prevalent genetic kidney disease leading to kidney failure. Tolvaptan, a vasopressin V2 receptor antagonist, is the only medication approved by the US Food and Drug Administration for slowing kidney growth in individuals with rapidly progressive ADPKD, but its long-term tolerability and effective implementation has yet to be studied, particularly in real-world clinical settings within the United States. Methods: This retrospective cohort study examined adults with ADPKD treated with tolvaptan at the University of Kansas Medical Center and the University of Iowa Hospitals & Clinics from May 2018 to April 2023. Data on demographics, clinical characteristics, tolvaptan dosage, and treatment duration were collected from electronic health records for an average follow-up duration of 28.2 months (interquartile range: 8.5–47.1 months). The study focused on examining tolvaptan dosage trends, treatment discontinuation reasons, and the impact of aquaretic side effects on dosage and adherence. Results: Of 134 patients, 27% stopped tolvaptan during the observational period, with 10.4% of the cohort withdrawing from treatment due to intolerance of aquaretic side effects. Most patients maintained a lower tolvaptan dosage (≤45/15 mg) than in clinical trials, with two thirds of individuals who underwent dosage adjustment undergoing net decrease in dosage. Adverse effects significantly influenced and dosage decisions, presenting a potential early barrier for adherence, particularly in female patients. Conclusions: The study highlights real-world challenges in the use of tolvaptan for ADPKD, particularly for side effects leading to high discontinuation rates and dosage adjustments. These findings underscore the need for standardized and improved management strategies to enhance tolerability and adherence, offering insights for future research and practice in the treatment of ADPKD with tolvaptan.
- Open Access
- 18 December 2024
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 73 (4) , 1082-1093
Effects of statins on kidney function in older adults
Background: The effect of statin therapy on kidney function among older adults is unclear. Objectives: To examine the association between statin use and changes in estimated glomerular filtration rate (eGFR) and urine albumin‐to‐creatinine ratio (UACR), positive or negative, in an older adult cohort with versus without chronic kidney disease (CKD) at baseline. Methods: This analysis included 18,056 participants aged ≥65 years with versus without CKD at baseline in a randomized trial of low‐dose aspirin, who had no prior cardiovascular events, major physical disability, or dementia initially. Outcome measures included eGFR and UACR. Linear mixed‐effects models were used to estimate the associations of baseline statin use versus no use with eGFR and UACR changes over time. The inverse‐probability of treatment‐weighting technique was used for all analyses to address confounding by indication due to the lack of randomization in treatment assignment. Results: Statin use was not associated with change in eGFR, UACR, or incident CKD in participants with or without CKD at baseline ( p > 0.05 for all associations). Subgroup analyses found no significant interactions between statin and age, sex, diabetes, country, and frailty status on any of the study outcomes. Conclusions: Among adults ≥65 years of age, with and without CKD, statin therapy was not associated with improved or worsened kidney function. This data suggests that the decision to use versus not use statins in this population may be ideally guided by factors other than kidney health.
- 18 December 2024
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 73 (4) , 1082-1093
Open AccessEffects of statins on kidney function in older adults
Background: The effect of statin therapy on kidney function among older adults is unclear. Objectives: To examine the association between statin use and changes in estimated glomerular filtration rate (eGFR) and urine albumin‐to‐creatinine ratio (UACR), positive or negative, in an older adult cohort with versus without chronic kidney disease (CKD) at baseline. Methods: This analysis included 18,056 participants aged ≥65 years with versus without CKD at baseline in a randomized trial of low‐dose aspirin, who had no prior cardiovascular events, major physical disability, or dementia initially. Outcome measures included eGFR and UACR. Linear mixed‐effects models were used to estimate the associations of baseline statin use versus no use with eGFR and UACR changes over time. The inverse‐probability of treatment‐weighting technique was used for all analyses to address confounding by indication due to the lack of randomization in treatment assignment. Results: Statin use was not associated with change in eGFR, UACR, or incident CKD in participants with or without CKD at baseline ( p > 0.05 for all associations). Subgroup analyses found no significant interactions between statin and age, sex, diabetes, country, and frailty status on any of the study outcomes. Conclusions: Among adults ≥65 years of age, with and without CKD, statin therapy was not associated with improved or worsened kidney function. This data suggests that the decision to use versus not use statins in this population may be ideally guided by factors other than kidney health.
- Open Access
- 5 November 2024
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 7 (11) , 1099-1106
Charting a course: Use of Electronic Health Records in skills‐based pharmacy education
Introduction: Competent navigation of an electronic health record (EHR) has become a critical skill for health professionals, and pharmacists need to be adept in EHR utilization given the extent of EHR involvement in routine medication management. Limited data exists related to current approaches to teaching EHR skills in pre‐Advanced Pharmacy Practice Experiences (pre‐APPE) pharmacy curricula.Objectives: The purpose of this study was to describe activities, utilization, and barriers to implementation of teaching EHRs (tEHRs) into pharmacy curricula in skills‐based courses.Methods: Faculty members of the Big Ten Academic Alliance Skills‐Based Education and Assessment Collaborative (BTAA‐SBEAC) were surveyed. The questionnaire included open‐ended questions related to tEHR type, curriculum placement, and current use of tEHRs, as well as barriers to incorporation of tEHRs in the curriculum. Inductive content analysis was used to evaluate qualitative responses.Results: A representative from all 10 colleges within the BTAA responded. Most programs focused on EHR teaching in the second and third years of the curriculum. All respondents reported having access to a tEHR for internal case building. The tEHR was used by all institutions to allow students to practice in gathering patient information as the first step in the Pharmacists' Patient Care Process. Other activities commonly performed using the tEHR included patient care documentation, medication order verification, prescription processing, and medication reconciliation. Faculty time and cost were barriers identified for successful tEHR implementation.Conclusion: Multiple skills are taught through the utilization of a tEHR among the colleges within the BTAA. These activities vary between institutions, and barriers exist that limit expansion and consistent integration across a skills‐based curriculum. Recognition of EHR utilization as an essential pharmacy skill can allow for development of formalized learning outcomes, leading to better support and integration throughout skills‐based courses.
- 5 November 2024
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 7 (11) , 1099-1106
Open AccessCharting a course: Use of Electronic Health Records in skills‐based pharmacy education
Introduction: Competent navigation of an electronic health record (EHR) has become a critical skill for health professionals, and pharmacists need to be adept in EHR utilization given the extent of EHR involvement in routine medication management. Limited data exists related to current approaches to teaching EHR skills in pre‐Advanced Pharmacy Practice Experiences (pre‐APPE) pharmacy curricula.Objectives: The purpose of this study was to describe activities, utilization, and barriers to implementation of teaching EHRs (tEHRs) into pharmacy curricula in skills‐based courses.Methods: Faculty members of the Big Ten Academic Alliance Skills‐Based Education and Assessment Collaborative (BTAA‐SBEAC) were surveyed. The questionnaire included open‐ended questions related to tEHR type, curriculum placement, and current use of tEHRs, as well as barriers to incorporation of tEHRs in the curriculum. Inductive content analysis was used to evaluate qualitative responses.Results: A representative from all 10 colleges within the BTAA responded. Most programs focused on EHR teaching in the second and third years of the curriculum. All respondents reported having access to a tEHR for internal case building. The tEHR was used by all institutions to allow students to practice in gathering patient information as the first step in the Pharmacists' Patient Care Process. Other activities commonly performed using the tEHR included patient care documentation, medication order verification, prescription processing, and medication reconciliation. Faculty time and cost were barriers identified for successful tEHR implementation.Conclusion: Multiple skills are taught through the utilization of a tEHR among the colleges within the BTAA. These activities vary between institutions, and barriers exist that limit expansion and consistent integration across a skills‐based curriculum. Recognition of EHR utilization as an essential pharmacy skill can allow for development of formalized learning outcomes, leading to better support and integration throughout skills‐based courses.
- 2 August 2024
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 7 (8) , 742-743
Clinical pharmacy and patient safety: Have we reached a golden era?
- 2 August 2024
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 7 (8) , 742-743
Clinical pharmacy and patient safety: Have we reached a golden era?
- 12 March 2024
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 64 (2) , 322-324
Earth Day: An opportunity for pharmacists to act
- 12 March 2024
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 64 (2) , 322-324
Earth Day: An opportunity for pharmacists to act
- 20 November 2023
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 42 (2) , 244-251
Long-term blood pressure variability and frailty risk in older adults
Introduction: In healthy older adults, the relationship between long-term, visit-to-visit variability in blood pressure (BP) and frailty is uncertain. Methods: Secondary analysis of blood pressure variability (BPV) and incident frailty in >13 000 participants ≥65–70 years enrolled in the ASPirin in Reducing Events in the Elderly (ASPREE) trial and its observational follow-up (ASPREE-XT). Participants were without dementia, physical disability, or cardiovascular disease at baseline. BPV was estimated using standard deviation of mean BP from three annual visits (baseline through the second annual follow-up). Frailty was defined using Fried phenotype and a frailty deficit accumulation index (FDAI). Participants with frailty during the BPV estimation period were excluded from the main analysis. Adjusted Cox proportional hazards regression evaluated the association between BPV and incident frailty, and linear mixed models for change in frailty scores, through a maximum of 9 years of follow-up. Results: Participants in the highest systolic BPV tertile were at higher risk of frailty compared to those in the lowest (referent) tertile of systolic BPV [Fried hazard ratio (HR) 1.17, 95% confidence interval (CI) 1.04–1.31; FDAI HR 1.18, 95% CI 1.07–1.30]. Findings were consistent when adjusted for multiple covariates and when stratified by antihypertensive use. Linear mixed models showed that higher systolic BPV was associated with increasing frailty score over time. Diastolic BPV was not consistently associated. Conclusions: High systolic BPV, independent of mean BP, is associated with increased risk of frailty in healthy older adults. Variability of BP across visits, even in healthy older adults, can convey important risk information beyond mean BP. Trial Registration: ClinicalTrials.gov NCT01038583 and ISRCTN83772183
- 20 November 2023
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 42 (2) , 244-251
Long-term blood pressure variability and frailty risk in older adults
Introduction: In healthy older adults, the relationship between long-term, visit-to-visit variability in blood pressure (BP) and frailty is uncertain. Methods: Secondary analysis of blood pressure variability (BPV) and incident frailty in >13 000 participants ≥65–70 years enrolled in the ASPirin in Reducing Events in the Elderly (ASPREE) trial and its observational follow-up (ASPREE-XT). Participants were without dementia, physical disability, or cardiovascular disease at baseline. BPV was estimated using standard deviation of mean BP from three annual visits (baseline through the second annual follow-up). Frailty was defined using Fried phenotype and a frailty deficit accumulation index (FDAI). Participants with frailty during the BPV estimation period were excluded from the main analysis. Adjusted Cox proportional hazards regression evaluated the association between BPV and incident frailty, and linear mixed models for change in frailty scores, through a maximum of 9 years of follow-up. Results: Participants in the highest systolic BPV tertile were at higher risk of frailty compared to those in the lowest (referent) tertile of systolic BPV [Fried hazard ratio (HR) 1.17, 95% confidence interval (CI) 1.04–1.31; FDAI HR 1.18, 95% CI 1.07–1.30]. Findings were consistent when adjusted for multiple covariates and when stratified by antihypertensive use. Linear mixed models showed that higher systolic BPV was associated with increasing frailty score over time. Diastolic BPV was not consistently associated. Conclusions: High systolic BPV, independent of mean BP, is associated with increased risk of frailty in healthy older adults. Variability of BP across visits, even in healthy older adults, can convey important risk information beyond mean BP. Trial Registration: ClinicalTrials.gov NCT01038583 and ISRCTN83772183